Rat FAAH (30-579) and firefly luciferase were expressed as GST-fusion proteins using the pGEX6P-1 vector in the E. coli strain JM109. Cells were grown at 37°C until the OD 600 reached 0.5-1, induced with 0.1 mM IPTG, and incubated at 20°C overnight. Cells were pelleted at 5000 rpm in a Sorvall 2C3C Plus centrifuge (H600A rotor) at 4°C for 15 min, then flash frozen in liquid nitrogen. E. coli pellets from 1 L of culture were thawed on ice, resuspended in 25 mL lysis buffer (50 mM Tris [pH 7.4], 500 mM NaCl, and 0.5% Tween 20) containing 1 mM phenylmethylsulfonyl fluoride, and disrupted by sonification (Branson Sonifier). Dithiothreitol (DTT) was added at 10 mM, and the resulting cell lysate was clarified by centrifugation at 35,000 rpm in a Beckman 50.2 Ti rotor for 60 min at 4°C. The supernatant was batch-bound to immobilized glutathione for 1 hr at 4°C, and the beads were washed with lysis buffer containing 10 mM DTT, followed by wash buffer (50 mM Tris [pH 8.1], 250 mM NaCl, and 10 mM DTT) and storage buffer (50 mM Tris [pH 7.4], 0.1 mM EDTA, 150 mM NaCl, 1 mM TCEP). Twenty units of PreScission Protease (GE Healthcare) were added, and incubated overnight at 4°C to cleave the GST-fusion and elute the untagged protein into storage buffer.
Purified Protein rFAAH Activity Assays
FAAH inhibitors were prepared at 4 μM in substrate buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 8 mM MgSO 4 , and 4 mM ATP). Luciferins and luciferin amides were prepared at 40 μM in substrate buffer. Luciferase and rFAAH were prepared at 400 nM in enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM TCEP, and 0.8 mg/mL BSA). In a black 96-well plate (Costar 3915), 25 μL FAAH inhibitor or substrate buffer was added to three wells each. rFAAH (25 μL) or enzyme buffer was added to the inhibitor and incubated at ambient temperature for 5 minutes. Luciferin or luciferin amide (25 μL) was then added to each well and incubated at ambient temperature for 20 minutes. Luminescence was then initiated by adding 25 μL of luciferase. Imaging was performed one minute after luciferase addition and integrated for 2-20s S4 at a final concentration of 1 μM FAAH inhibitor, 10 μM luciferin, 100 nM rFAAH, and 100 nM luciferase.
Purified rFAAH Dose-Response Assays
Purified rFAAH was prepared at concentrations ranging from 8 μM to 3.91 nM in enzyme buffer.
Luciferin amides were prepared at 20 μM in substrate buffer. Luciferase was prepared at 400 nM in enzyme buffer. In a black 96-well plate (Costar 3915), 50 μL of each luciferin amide was added per well. rFAAH (25 μL) was then added to the amide and incubated at ambient temperature for 30 minutes. Luminescence was then initiated by adding 25 μL of luciferase.
Imaging was performed one minute after luciferase addition for 2-20s at a final concentration of 2000 nM to 0.977 nM rFAAH, 10 μM luciferin amide, and 100 nM luciferase.
Luciferin Amide Inhibitor Assays with Purified Luciferase
Luciferin amides were prepared at 40 μM or 100 μM in substrate buffer. Luciferins were prepared at concentrations from 1000 μM to 0.488 μM in substrate buffer. Luciferase was prepared at 200 nM in enzyme buffer. In a black 96-well plate (Costar 3915), 25 μL luciferin amide or substrate buffer was added to three rows each. Luciferin (25 μL) was added to the luciferin amide. Luminescence was then initiated by adding 50 μL of luciferase. Imaging was performed one minute after luciferase addition for 2-20s at a final concentration of 0 μM, 10 μM, or 25 μM luciferin amide, 250 μM to 0.122 μM luciferin, and 100 nM luciferase.
Cell Culture
Chinese hamster ovary (CHO) cells and HeLa cells were grown in a CO 2 incubator at 37°C with 5% CO 2 and were cultured in F-12K Nutrient Mixture (GIBCO) and Dulbecco's Modified Eagle's Medium (DMEM) (GIBCO) respectively. Both media were supplemented with 10% fetal bovine serum and 100 U/mL penicillin/streptomycin. GFP)L2G85Chco/FathJ) were purchased from Jackson Laboratories (Bar Harbor, ME).
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Transfections
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Striatal injection of AAV9-CMV-luc2 into FVB mice was performed as previously described
18
.
Tail-vein injection of AAV
FVB mice were injected in the lateral tail vein with 1x10 11 particles of AAV9-CMV-luc2 luciferase 18 suspended in sterile filtered PBS at a final volume of 200 μL. The mice were held under a heat lamp to warm the tail for better visualization of the lateral tail vein due to vasodilation and then placed into a Tailveiner (Braintree Scientific, Braintree, MA). The tails were cleaned with a 70% isopropyl alcohol wipe and injection was performed using a 27.5 gauge needle. Once the needle was withdrawn, the tail was compressed with sterile gauze to ensure complete homeostasis. The mice were monitored afterwards for recovery of normal behavior before returning to their colony. Imaging was performed weeks to months after AAV injection.
Substrate and FAAH Inhibitor Preparation for Mouse Injection
All FAAH inhibitors were prepared by direct dissolution into 18:1:1 PBS:Kolliphor:ethanol and sterile filtering through a 0.22 μm syringe filter. Each inhibitor was injected intraperitoneally (i.p.)
at 5 μL/g mouse. Inhibitors were prepared at 2 mg/mL, 0.2 mg/mL, 0.02 mg/mL, and 0.002 mg/mL to achieve final concentrations of 10 mg/kg, 1 mg/kg, 0.1 mg/kg, and 0.01 mg/kg respectively. Due to limited solubility, URB597 was prepared at 0.4 mg/mL and injected at 10 μL/g to achieve a dose of 4 mg/kg. D-luciferin (100 mM) and CycLuc1 (5 mM) were prepared by direct dissolution into PBS and were sterile filtered through a 0.22 μm syringe filter. All other luciferins were prepared by diluting a 50 mM DMSO stock into PBS and sterile filtering through a 0.22 μm syringe filter. CycLuc1
ethyl ester was not soluble in PBS and was therefore prepared by diluting the 50 mM DMSO stock into 18:1:1 PBS:Kolliphor:ethanol. Each substrate was injected i.p. at 4 μL/g mouse.
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Substrates were prepared at 100 mM (D-Luciferin), 5 mM (CycLuc1), 250 μM (substrates for AAV mice), and 100 μM (substrates for FVB-Tg[CAG-luc] mice) to achieve final concentrations of 400 μmol/kg, 20 μmol/kg, 1 μmol/kg, and 0.4 μmol/kg respectively.
Bioluminescence Imaging of Mice
Each mouse was weighed to determine substrate and/or FAAH inhibitor dosing and anesthetized using 2.5% isoflurane in 1 L/min oxygen. FAAH inhibitors were injected i.p. at 5 μL/g mouse 30 minutes prior to luciferin injection. Luciferin substrate was injected i.p. at 4 μL/g mouse and mice were imaged dorsally at 10 minutes and ventrally at 13 minutes. (S)-2-amino-3-mercaptopropanamide (2): D-cysteine methyl ester hydrochloride (500 mg, 2.912 mmol) was dissolved in aqueous ammonium hydroxide solution (2 mL) and the mixture was stirred at room temperature under argon for 2h. Solvents were evaporated under reduced pressure and the resulting white solid was used in the next step without further purification (300 mg, 86%). in 50 mM aqueous sodium phosphate buffer (pH 8.0, 2 mL) and degassed using argon. This solution was added to 3 (10 mg, 0.046 mmol) in degassed methanol (2 mL). The reaction mixture was stirred at room temperature for 2h, diluted with sodium phosphate buffer and extracted with ethyl acetate (2 × 30 mL). The combined organic layers were washed with water (2 × 20 mL), dried (Na 2 SO 4 ), filtered and evaporated to afford 4 as a yellow solid. The crude compound was purified by flash chromatography on silica gel eluting with EtOAc-hexanes (7:3)
to afford the product 4 as a yellow solid (12 mg, 80%). with sodium phosphate buffer and extracted with ethyl acetate (2 × 30 mL). The combined organic layers were washed with water (2 × 30 mL), dried (Na 2 SO 4 ), filtered and evaporated to afford 6 as a yellow solid. The crude compound was purified by flash chromatography on silica gel eluting with EtOAc-hexanes (8:2) to afford the product 6 as a yellow solid (10 mg, 67%). 4, 166.9, 154.6, 152.3, 147.3, 137.2, 131.9, 120.6, 98.7, 79.0, 48.0, 35.2, 29.4 
D-luciferin-amide [(S)-2-(6-hydroxybenzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxamide] (8):
D-Cysteine amide 2 (10 mg, 0.083 mmol) was dissolved in 50 mM aqueous sodium phosphate buffer (pH 8.0, 2 mL) and degassed using argon. This solution was added to 7 (10 mg, 0.056 mmol) in degassed methanol (2 mL). The reaction was stirred for 2 h, diluted with sodium phosphate buffer and extracted with ethyl acetate (2 × 30 mL). The combined organic layers were washed with water (2 × 30 mL), dried (Na 2 SO 4 ), filtered, and evaporated.
The crude compound was purified by flash chromatography on silica gel eluting with EtOAchexanes (8:2) to afford the product 8 as a white solid (13 mg, 83%). mmol) was dissolved in 40% aqueous methylamine solution (3 mL) and the mixture was stirred at room temperature under argon for 2h. The solvents were evaporated under reduced pressure and the resulting white solid contains both product 10 and the corresponding disulphide. The crude compound was directly used in the next step. D-cysteine methylamide 10 (10 mg, 0.074 mmol) was dissolved in 50 mM aqueous sodium phosphate buffer (pH 8.0, 2 mL) and degassed using argon. This solution was added to 11 (10 mg, 0.049 mmol) in degassed methanol (2 mL).
The reaction mixture was stirred at room temperature for 2 h, diluted with sodium phosphate buffer and extracted with ethyl acetate (2 × 30 mL). The combined organic layers were washed with water (2 × 30 mL), dried (Na 2 SO 4 ), filtered, and evaporated to afford 12 as a yellow solid.
The crude compound was purified by flash chromatography on silica gel eluting with EtOAchexanes (7:3) to afford the product 12 as a yellow solid (12 mg, 77%). 154.8, 151.9, 147.4, 137.1, 131.9, 120.6, 99.0, 79.2, 48.0, 35.7, 29.4, 26.5 was dissolved in 50 mL ethanol solution and gentle steam of HCl gas was bubbled through the solution for 80 minutes and resulting solution was then stirred at room temperature overnight. Solvent was removed under reduced pressure. To the resulting white residue, chloroform (10 mL) was added, stirred for 10 min and resulting slurry was filtered, washed with chloroform (10 mL) and dried under high vacuum to give the product 14 as a white solid in quantitative yield. 6, 166.7, 155.3, 151.6, 147.5, 137.2, 131.8, 120.4, 99.3, 78.5, 62.2, 48.0, 35.4, 29.4, 14.4 
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